A Safety and Efficacy Study in Patients With Gastric Cancer
Gastric Cancer
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring Gastric Cancer
Eligibility Criteria
Inclusion Criteria:
A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:
- Has given written informed consent
- Has histologically confirmed, unresectable, locally advanced (Stage IV) or metastatic gastric cancer, including adenocarcinoma of the gastro-esophageal junction
Has measurable or evaluable but non-measurable disease, defined as follows:
- Measurable Disease - Patients with measurable disease as defined by RECIST criteria, i.e., the presence of at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter >_ 20 mm using conventional techniques or >_ 10 mm using spiral Computed Tomography (CT)scan. Locally recurrent disease (other than primary) is accepted if there is at least one measurable lesion (i.e. peritoneal mass, lymph node, etc.)
- Evaluable but Non-measurable Disease - Patients with all lesions below the limits defined above for measureable disease (i.e., longest diameter < 20 mm with conventional techniques or < 10 mm with spiral CT) excluding those patients with only a primary lesion and/or with only non-evaluable cancer such as bone metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis of the skin or lung, previously irradiated lesions not in progression, or peritoneal carcinomatosis < 10 mm in diameter with conventional imaging techniques.
- No prior palliative chemotherapy is permitted. Adjuvant and /or neo-adjuvant chemotherapy is permitted if more than 12 months have elapsed between the end of adjuvant or neo-adjuvant therapy and first recurrence. This does not qualify as 1st line therapy.
- Is able to take medications orally
- Is >_ 18 years of age
- Is at least 3 weeks from prior major surgery
- Is at least 4 weeks from prior radiotherapy
- Has a ECOG performance status 0 to 1
Has adequate organ function as defined by the following criteria:
- AST (SGOT) and ALT (SGPT) <_ 2.5 x ULN; if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) <_ 5 x ULN
- Total serum bilirubin of <_ 1.5 x ULN
- Absolute granulocyte count of >_ 1,500/mm (i.e. >_ 1.5 x 10/L by International Units (IU)
- Platelet count >_ 100,000/mm (IU: >_ 100 x 10/L
- Hemoglobin value of >_ 9.0 g/dL
- Calculated creatinine clearance >_ 60 mL/min (Cockcroft-Gault formula)
- Is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
Exclusion Criteria:
Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:
Has had a treatment with any of the following within the specified timeframe prior to study drug administration:
- Any prior palliative chemotherapy or any previous therapy for malignancy, including any chemotherapy, immunotherapy, biologic or hormonal therapy, within the past 5 years.
- Adjuvant or neo-adjuvant therapy within the past 12 months
- Concurrent treatment with any investigational anti-cancer agent
- Prior cisplatin as neo-adjuvant and /or adjuvant chemotherapy with cumulative dose > 300 mg/m
- > 25% of marrow-bearing bone radiated
- Concurrent treatment with an investigational agent or within 30 days from randomization
- Concurrent enrollment in another clinical study
Has a serious illness or medical condition(s) including, but not limited to the following:
- Known brain or leptomeningeal metastases
- Uncontrolled ascites requiring drainage at least twice a week
- Other malignancies within the past 5 years, except adequately treated carcinoma-in-situ of the cervix or non-melanoma skin cancer
- Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure New York Heart Association (NYHA) class III or IV
- Chronic nausea, vomiting or diarrhea
- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS-related illness
- Psychiatric disorder that may interfere with consent and/or protocol compliance
- Known neuropathy, Grade 2 or higher
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgement of the Investigator would make the patient inappropriate for entry into this study
Is receiving concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:
- Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1 activity)
- Allopurinol (may diminish S-1 activity
- Phenytoin (S-1 may enhance phenytoin activity)
- Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity)
Is receiving concomitant treatment with drugs interacting with 5-FU:
- Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole(may enhance 5-FU activity)
- Allopurinol (may diminish 5-FU activity)
- Phenytoin (5-FU may enhance phenytoin activity)
Is receiving concomitant treatment with drugs interacting with cisplatin:
- Phenytoin (cisplatin may diminish phenytoin activity)
- Aminoglycosides (should be avoided within 8 days after cisplatin administration)
- Ethyol (may diminish cisplatin activity
- Is a pregnant or lactating female
- Has known hypersensitivity to 5-FU or cisplatin
- Patients with reproductive potential who refuse to use an adequate means of contraception (including male patients)
Sites / Locations
- Clearview Cancer Center
- Saint Joseph Medical Center
- Dr. Ronald Yanagihara
- Norris Cancer Center
- Comprehensive Cancer Center
- Saint Francis Memorial Hospital
- Premiere Oncology
- Western Hematology/Oncology
- Broward Oncology Associates
- Alexandar Rosemurgy
- Palm Beach Cancer Institute
- Straub Clinic and Hospital
- Robert H. Lurie Comprehensive Cancer Center
- University of Chicago Medical Center
- Oncology and Hematology
- St. Lukes Cancer Care Center
- Neuroscience Center
- St. Louis University Cancer Center
- Southern Nevada Cancer Research Foundation
- AHS Lovelace Medical Group,LLC
- New Mexico Cancer Center Associates
- University of New Mexico
- Hoo Chun, MD
- Hematology/Oncology Associates of Rockland
- New Bern Cancer Care
- Abramson Cancer Center
- Thomas Jefferson University
- Charleston Cancer Center
- Associates in Oncology and Hematology
- Lexington Oncology Associates
- MD Anderson Cancer Center
- University of Wisconsin Comprehensive Cancer Center
- CHUM Hopital Saint-Luc
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
A
B
In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.